In an attempt to address what they call America’s “destructive spending pattern,” members of the U.S. House Appropriations
Committee have proposed a $285 million cut to the U.S. Food and Drug Administration’s (FDA) 2012 spending bill.
There is strong demand for
new anti-infectives, but major factors are slowing down their commercialization. There are, however, a variety of promising initiatives, including advances
involving non-antibiotic anti-infectives and host defense proteins.
For the stem cell research arena, the main source of public confusion and debate centers on the use of cell lines derived from human embryos. While society
has yet to reach consensus on the ethical and moral dilemmas presented by hESC research, it’s important to remember that it’s not the only form of stem cell